A case of infliximab-induced psoriasis

Dermatology Online Journal

Volumn 14, Issue 11, 2008, Pages

  Richetta, A G ^a   Mattozzi, C ^a   Carlomagno, V ^a   Maiani, E ^a   Carboni, V ^a   Giancristoforo, S ^a   D'Epiro, S ^a   Bruni, F ^a   Calvieri, S ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CYCLOSPORIN; CYTOKINE; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLERGIC REACTION; ANAMNESIS; ANKYLOSING SPONDYLITIS; ARTICLE; BACTERIAL INFECTION; BACTERIUM CULTURE; BLOOD ANALYSIS; BLOOD EXAMINATION; CASE REPORT; CELL INFILTRATION; CLINICAL FEATURE; CROHN DISEASE; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ERYTHEMA; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; KERATOSIS; KLEBSIELLA OXYTOCA; LYMPHOCYTOPENIA; MALE; NEUTROPHILIA; PRURITUS; PSORIASIS; RASH; SKIN BIOPSY; SKIN DEFECT; SKIN FLORA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; THROAT CULTURE; TREATMENT DURATION; TREATMENT OUTCOME; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTION; MICROBIOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PHARYNGITIS; PHYSIOLOGY; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KLEBSIELLA INFECTIONS; KLEBSIELLA OXYTOCA; MALE; PHARYNGITIS; PSORIASIS; SPONDYLITIS, ANKYLOSING; STAPHYLOCOCCAL INFECTIONS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 57049143765     PISSN: None     EISSN: 10872108     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Nash PT, Florin THJ. Tumour necrosis factor inhibitors. MJA 2005; 183(4): 205-208. PubMed.
2. Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Rowert J, Audring H, Kary S, Burmester GR, Sterry W, Worm M. Cutaneous side-effects in patients with rheumatic disease during application of tumor necrosis factor-alpha antagonists. Br J Dermatol 2007 Mar; 156(3): 486-91. PubMed.
3. Lebas D, Staumont-Sallé D, Solau-Gervais E, Flipo RM, Delaporte E. Cutaneous manifestations during treatment with TNF-alpha blockers: 11 cases. Ann Dermatol Venereol 2007 Apr; 134(4 Pt 1): 337-42. PubMed.
4. Beuthien W, Mellinghoff HU, Von Kempis J. Skin reaction to adalimumab. Arthritis Rheum. 2004 May; 50(5): 1690-2. PubMed.
5. Devos SA, Van Den Bossche N, De Vos M, Naeyaert JM. Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology. 2003; 206(4): 388-90. PubMed.
6. Nikas SN, Voulgari PV, Drosos AA. Urticaria and angiedema-like skin reactions in a patient treated with adalimumab. Clin Rheumatol. 2007 May; 26(5): 787-8. PubMed.
7. O'Shea JJ, Ma A, Lipsky P. Cytokines and autoimmunity. Nat Rev Immunol 2002;2:37-45. PubMed .
8. Kimber I, Cumberbatch M, Dearman RJ, Bhushan M, Griffiths CEM. Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization. Br J Dermatol 2000;142:401-12. PubMed.
9. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M. Psoriasis as a model for T-cell-mediated disease: Immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a monoclonal antibody. Arch Derm 2002;138:591-600. PubMed.
10. Bhushan M, McLaughlin B, Weiss JB, Griffiths CE. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol. 1999 Dec;141(6):1054-60. PubMed
11. Simonetti O, Lucarini G, Goteri G, Zizzi A, Biagini G, Lo Muzio L, Offidani A. VEGF is likely a key factor in the link between inflammation and angiogenesis in psoriasis: result of an immunohistochemical study. Int J Immunopathol Pharmacol. 2006 Oct-Dec;19(4):751-60. PubMed.
12. Mease P. TNF-α therapy in psoriasis arthritis and psoriasis. Ann Rheum Dis 2004; 63: 755-758. PubMed.
13. Cordiali-Fei P, Trento E, D'Agosto G, Bordignon V, Mussi A, Ardigo M, Mastroianni A, Vento A, Solivetti F, Berardesca E, Ensoli F. Decresed levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriasic arthritis after therapy with anti-TNF-alpha. J Autoimmune Dis. 2006 Oct 5;3:5. PubMed.
14. P. P. Sfikakis, A. Iliopoulos, A. Elezoglou, C. Kittas, and A. Stratigos. Psoriasis Induced by Anti-Tumor Necrosis Factor Therapy: A Paradoxical Adverse Reaction. Arthritis Rheum. 2005 Aug; 52(8): 2513-2518. PubMed.
15. Takahashi H, Hashimoto Y, Ishida-Yamamoto A, Ashida T, Kohogo Y, Iizuka H. Psoriasiform and pustular eruption induced by infliximab. Journ Dermatol. 2007; 34: 468-472. PubMed.
16. Kary S, Worm M, Audring H, Huscher D, Renelt M, Sorensen H, Stander E, Maaß U, Lee H, Sterry W, Burmester GR. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor-α antagonists. Ann Rheum Dis 2006;65: 405-407. PubMed.
17. Severs GA, Lawlor TH, Purcell SM, Adler DJ, Thompson R. Cutaneous adverse reaction to infliximab: report of psoriasis developing in 3 patients. Cutis 2007 Sep; 80(3): 231-7. PubMed.
18. Heymann WR. Tumor necrosis factor inhibitor-induced pustular psoriasis? J Am Acad Dermatol. 2007 ; 56(2): 327-328. PubMed.
19. Berg EL, Yoshino T, Rott LS, Robinson MK, Warnock RA, Kishimoto TK, et al. The cutaneous lymphocyte antigen is a skin lymphocyte homing receptor for the vascular lectin endothelial cell-leukocyte adhesion molecule 1. J Exp Med 1991;174:1461-6. PubMed.
20. Aeberli D, Seitz M, Juni P, Villiger PM. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-α inhibitors. Rheumatology (Oxford) 2005;44:172-5. PubMed.
21. Rottman JB, Smith TL, Ganley KG, Kikuchi T, Krueger JG. Potential role of the chemokine receptors CXCR3, CCR4, and the integrin _E_7 in the pathogenesis of psoriasis vulgaris. Lab Invest 2001;81:335-47. PubMed.